Bildgebungssonde mit Selektivität für lösliches Tau-aggregiertes  Protein

sikopharma

sikopharma

A fluorescent molecular imaging probe with selectivity for soluble tau-aggregated   protein

Soluble forms of aggregated, misfolded tau protein, commonly referred to as oligomers, are considered to be the most toxic species of the various assemblies that are the pathological components of neurodegenerative diseases. Therefore, there is a critical biomedical  need for imaging probes that can identify and quantify them. We  designed and synthesized a novel fluorescent probepTP-TFE, for which binding and selectivity  profiles towards aggregated tau and Aβ proteins were examined  . Our results have shown that   pTP-TFE   is selective for early forms of soluble tau aggregates, with a high affinity of the dissociation constant ( Okay   d  ) = 66 nM and a ten-fold selectivity towards mature tau fibrils.

Darüber hinaus fanden wir, dass  pTP-TFE  für Tau gegenüber Aβ-Aggregaten selektiv ist und eine gute Zellpermeabilität aufwies . Diese Selektivität von  pTP-TFE  gegenüber frühen Formen von aggregiertem Tau-Protein  ex vivo  wurde auch durch Studien an menschlichem Hirngewebe unterstützt, das Tau- und Aβ-Pathologie enthält. Nach unserem besten Wissen ist dies das erste fluoreszierende Molekül, über das berichtet wird, dass dieses Selektivitätsprofil aufweist, was darauf hindeutet, dass  pTP-TFE  ein einzigartiger Sondenkandidat für die bildgebende Detektion von frühen Stadien der Alzheimer-Krankheit und anderer Tauopathien ist.

Die orale Verabreichung von Mind  Protein  kombiniert mit Probiotika induziert Immuntoleranz Durch die Tryptophan Pathway

Übermäßige Entzündungen führen zu sekundären Immunschäden nach Schädel-Hirn-Trauma (SHT). Die Darmschleimhaut ist aufgrund der Darm-Hirn-Achsen-Regulierung eine Schlüsselkomponente der Immuntoleranz, aber die heilende Wirkung ist nicht optimum. Eine Darmfunktionsstörung beeinträchtigt die Etablierung einer Immuntoleranz bei Patienten mit SHT. Daher haben wir Gehirn oral verabreichtProtein (BP) kombiniert mit Probiotika, um eine Immuntoleranz zu induzieren, und erforschte den Mechanismus, durch den die Homöostase der Mikrobiota zur Verstärkung der heilenden Wirkung von BPs beiträgt. Hierin zeigten wir, dass Patienten mit TBI und chirurgischen Hirnverletzungsmodellen (SBI) von Ratten eine offensichtliche Dysbiose aufwiesen. Insbesondere die Darmbarriere, proinflammatorische Zytokine und die Aktivierung von Mikroglia zeigten, dass übermäßige Entzündungsschäden in der kombinierten Gruppe (orale Verabreichung von BP in Kombination mit Probiotika) besser kontrolliert wurden als in der BP-Gruppe (orale Verabreichung von BP). Grundsätzlich zeigte eine Tandem-Mass-Tag (TMT)-basierte quantitative Proteomik-Analyse, dass BP und Probiotika bevorzugt Strive-bezogene Signalwege beeinflussen.

Eine Reihe von Experimenten bestätigte außerdem, dass die Expression des Indoleamin-2,3-Dioxygenase (IDO)/Kyurenin (Kyn)/Aryl-Kohlenwasserstoff-Rezeptor (AhR) in der BP-Gruppe hoch warfare, während Tryptophan-Hydroxylase 1(TpH1)/5-Hydroxytryptamin (5-HT ) nur in der kombinierten Gruppe geändert. Diese Studie legt nahe, dass Probiotika die Wirksamkeit der oralen BP-induzierten Immuntoleranz über den Strive-Weg verbessern können .

 

sikopharma
sikopharma

DNAAF5 Polyclonal Antibody

A58814-050 50 ul
EUR 302.5

DNAAF5 Polyclonal Antibody

A58814-100 100 ul
EUR 423.5

DNAAF5 Polyclonal Antibody

A58814
  • EUR 684.66
  • EUR 117.70
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

DNAAF5 Antibody, HRP conjugated

1-CSB-PA771471LB01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

DNAAF5 Antibody, FITC conjugated

1-CSB-PA771471LC01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

DNAAF5 Antibody, Biotin conjugated

1-CSB-PA771471LD01HU
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against DNAAF5. Recognizes DNAAF5 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

DNAAF5 Polyclonal Antibody, Biotin Conjugated

A58815-050 50 ul
EUR 302.5

DNAAF5 Polyclonal Antibody, Biotin Conjugated

A58815-100 100 ul
EUR 423.5

DNAAF5 Polyclonal Antibody, FITC Conjugated

A58816-050 50 ul
EUR 302.5

DNAAF5 Polyclonal Antibody, FITC Conjugated

A58816-100 100 ul
EUR 423.5

DNAAF5 Polyclonal Antibody, HRP Conjugated

A58817-050 50 ul
EUR 302.5

DNAAF5 Polyclonal Antibody, HRP Conjugated

A58817-100 100 ul
EUR 423.5

DNAAF5 Polyclonal Antibody, Biotin Conjugated

A58815
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

DNAAF5 Polyclonal Antibody, FITC Conjugated

A58816
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

DNAAF5 Polyclonal Antibody, HRP Conjugated

A58817
  • EUR 684.66
  • EUR 302.50
  • EUR 423.50
  • 100 µg
  • 50 ul
  • 100 ul

Human Dynein Assembly Factor 5, Axonemal / HEATR2 (DNAAF5) ELISA Kit

abx387761-96tests 96 tests
EUR 1093.2

Positive control tissue section for each individua

Control-Slides-for-each-antibody Set of 25
EUR 355
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE

CD11b Antibody Antibody

ABD2911 100 ug
EUR 525.6

ASAP1 antibody Antibody

DF8746 200ul
EUR 420

anti- Antibody^Polyclonal antibody control antibody

LSMab09882 100 ug
EUR 525.6

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.08ML 0.08 ml
EUR 165

ARHGDIA Antibody / RHOGDI Antibody

F54788-0.4ML 0.4 ml
EUR 379

Antibody

A1360-500 each Ask for price

Anti-Glycolipid Antibody (AGA) Antibody

20-abx004855
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Ly1 Antibody Reactive (LYAR) Antibody

20-abx008109
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Ly1 Antibody Reactive (LYAR) Antibody

20-abx123734
  • EUR 493.20
  • EUR 710.40
  • 100 ul
  • 200 ul

Ly1 Antibody Reactive (LYAR) Antibody

20-abx014333
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-400ul 400 ul
EUR 627.6

Ly1 Antibody Reactive (LYAR) Antibody

abx033330-80l 80 µl
EUR 343.2

Anti-Glycolipid Antibody (AGA) Antibody

abx036399-100ug 100 ug
EUR 469.2

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319900
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319901
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319905
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody

20-abx319913
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycolipid Antibody (AGA) Antibody

abx230204-100ug 100 ug
EUR 577.2

Ly1 Antibody Reactive (LYAR) Antibody

20-abx324434
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

20-abx311665
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody

abx234901-100ug 100 ug
EUR 661.2

Anti-Anti-SEPT6 antibody antibody

STJ11100949 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined.

Anti-Anti-SEPT9 Antibody antibody

STJ111369 100 µl
EUR 332.4
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described.

Anti-Anti-SEPT11 Antibody antibody

STJ111530 100 µl
EUR 332.4

Anti-Anti-SEPT4 Antibody antibody

STJ112276 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer.

Anti-Anti-MARCH9 Antibody antibody

STJ112609 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ113941 100 µl
EUR 332.4

Anti-Anti-SEPT11 Antibody antibody

STJ114081 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ114819 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-MARCH8 Antibody antibody

STJ114828 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ116214 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT8 Antibody antibody

STJ117206 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT12 Antibody antibody

STJ117759 100 µl
EUR 332.4
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-MARCH6 Antibody antibody

STJ118549 100 µl
EUR 332.4

Anti-Anti-MARCH6 Antibody antibody

STJ118550 100 µl
EUR 332.4

Anti-Anti-MARCH7 Antibody antibody

STJ118752 100 µl
EUR 332.4

Anti-Anti-SEPT3 Antibody antibody

STJ118990 100 µl
EUR 332.4

Anti-Anti-SEPT2 Antibody antibody

STJ28365 100 µl
EUR 332.4

Anti-Anti-SEPT7 Antibody antibody

STJ28963 100 µl
EUR 332.4
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19.

Anti-Anti-SEPT2 Antibody antibody

STJ25475 100 µl
EUR 332.4

Anti-Anti-SEPT5 Antibody antibody

STJ25477 100 µl
EUR 332.4
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced.

Anti-Anti-SEPT8 Antibody antibody

STJ25479 100 µl
EUR 332.4
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Anti-Anti-SEPT1 antibody antibody

STJ119580 100 µl
EUR 332.4
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012]

CLCN5 Antibody / CIC-5 antibody

RQ6462 100ug
EUR 419
Description: The CLCN5 gene encodes the chloride channel Cl-/H+ exchanger ClC-5. This gene encodes a member of the ClC family of chloride ion channels and ion transporters. The encoded protein is primarily localized to endosomal membranes and may function to facilitate albumin uptake by the renal proximal tubule. Mutations in this gene have been found in Dent disease and renal tubular disorders complicated by nephrolithiasis. Alternatively spliced transcript variants have been found for this gene.

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-100ul 100ul
EUR 399.6

Cytokeratin 7 antibody-Cytoskeleton Marker Antibody

48169-50ul 50ul
EUR 286.8

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-01mg 0,1 mg
EUR 321
Description: anti-CD22 monoclonal antibody

Anti CD22 Antibody: CD22 Monoclonal Antibody

065-A-1000ug 1000 ug
EUR 1539
Description: anti-CD22 monoclonal antibody

Antibody Pair to ApoA-V antibody

10R-1876 100 ul
EUR 781.2
Description: Mouse monoclonal Antibody Pair to ApoA-V antibody

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103034
  • EUR 543.60
  • EUR 159.60
  • EUR 1562.40
  • EUR 744.00
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103035
  • EUR 560.40
  • EUR 159.60
  • EUR 1612.80
  • EUR 760.80
  • EUR 410.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Ly1 Antibody Reactive Homolog (LYAR) Antibody

20-abx103036
  • EUR 577.20
  • EUR 159.60
  • EUR 1696.80
  • EUR 794.40
  • EUR 427.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Hepatitis C Virus Antibody (HCV) Antibody

abx023924-1mg 1 mg
EUR 1446

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319902
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319903
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319904
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319906
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319907
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319908
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319914
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319915
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319916
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (HRP)

20-abx319929
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (FITC)

20-abx319930
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein Antibody (GP) Antibody (Biotin)

20-abx319931
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (HRP)

20-abx311666
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (FITC)

20-abx311667
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ly1 Antibody Reactive (LYAR) Antibody (Biotin)

20-abx311668
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Glycoprotein 210 Antibody (gp210) Antibody

abx233571-100ug 100 ug
EUR 577.2

Anti Deoxyribonucleic Acid Antibody (DNA) Antibody

abx411057-50ug 50 ug
EUR 710.4

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

Goat anti- human Antibody^Polyclonal antibody

LSMab09896 100 ug
EUR 525.6

Antibody for Human alpha Tubulin Antibody

SPC-692D 0.1mg
EUR 424.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A390 0.1mg
EUR 481.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A488 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A565 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A594 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A633 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A655 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A680 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680.

Antibody for Human alpha Tubulin Antibody

SPC-692D-A700 0.1mg
EUR 480
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700.

Antibody for Human alpha Tubulin Antibody

SPC-692D-ALP 0.1mg
EUR 472.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase.

Antibody for Human alpha Tubulin Antibody

SPC-692D-APC 0.1mg
EUR 478.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC .

Antibody for Human alpha Tubulin Antibody

SPC-692D-APCCY7 0.1mg
EUR 565.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7.

Antibody for Human alpha Tubulin Antibody

SPC-692D-BI 0.1mg
EUR 475.2
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY350 0.1mg
EUR 496.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY405 0.1mg
EUR 483.6
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY488 0.1mg
EUR 471.6
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY594 0.1mg
EUR 474
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594.

Antibody for Human alpha Tubulin Antibody

SPC-692D-DY633 0.1mg
EUR 468
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633.

Antibody for Human alpha Tubulin Antibody

SPC-692D-FITC 0.1mg
EUR 470.4
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC.

Antibody for Human alpha Tubulin Antibody

SPC-692D-HRP 0.1mg
EUR 465.6
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP.

Antibody for Human alpha Tubulin Antibody

SPC-692D-P594 0.1mg
EUR 488.4
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594.

Antibody for Human alpha Tubulin Antibody

SPC-692D-PCP 0.1mg
EUR 478.8
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP.

Antibody for Human alpha Tubulin Antibody

SPC-692D-RPE 0.1mg
EUR 476.4
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE .

Antibody for Human alpha Tubulin Antibody

SPC-692D-STR 0.1mg
EUR 477.6
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin.

Antibody for Human alpha Tubulin Antibody

SPC-692S 0.012mg
EUR 78
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated.

Anti-Noelin Antibody BIOTIN Antibody BIOTIN

STJ501938 100 µg
EUR 703.2

Anti-Noelin Antibody FITC Antibody FITC

STJ501939 100 µg
EUR 703.2

Anti-Noelin Antibody BIOTIN Antibody BIOTIN

STJ501940 100 µg
EUR 703.2

Anti-Noelin Antibody FITC Antibody FITC

STJ501941 100 µg
EUR 703.2

Anti-IgG1 Negative Control Antibody antibody

STJ16100881 1 mL
EUR 573.6

Lambda Light Chain Antibody / Lambda Antibody

R20161-100UG 100ug
EUR 409

Lambda Light Chain Antibody / Lambda Antibody

R20161BTN-50UG 50ug
EUR 409

Lambda Light Chain Antibody / Lambda Antibody

R20161SAF-250UG 250ug
EUR 979

Lambda Light Chain Antibody / Lambda Antibody

R20179-100UG 100ug
EUR 409

Lambda Light Chain Antibody / Lambda Antibody

R20179BTN-50UG 50ug
EUR 409

Lambda Light Chain Antibody / Lambda Antibody

R20179SAF-250UG 250ug
EUR 979

Lambda Light Chain Antibody / Lambda Antibody

RQ4975 100ul
EUR 419

Lambda Light Chain Antibody / Lambda Antibody

V9032-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V9032-20UG 20 ug
EUR 219
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V9032IHC-7ML 7 ml
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V9032SAF-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3151-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3151-20UG 20 ug
EUR 219
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3151CF488-100T 100 Tests
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3151IHC-7ML 7 ml
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3151SAF-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3152-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3152-20UG 20 ug
EUR 219
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3152SAF-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3261-100UG 100 ug
EUR 499
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm.

Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki]

Lambda Light Chain Antibody / Lambda Antibody

V3261-20UG 20 ug
EUR 219
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm.

Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki]

Lambda Light Chain Antibody / Lambda Antibody

V3261SAF-100UG 100 ug
EUR 499
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm.

Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki]

Lambda Light Chain Antibody / Lambda Antibody

V3262-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3262-20UG 20 ug
EUR 219
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V3262SAF-100UG 100 ug
EUR 499
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2151-100UG 100 ug
EUR 499
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2151-20UG 20 ug
EUR 219
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2151SAF-100UG 100 ug
EUR 499
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2153-100UG 100 ug
EUR 499
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2153-20UG 20 ug
EUR 219
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2153CF488-100T 100 Tests
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2153IHC-7ML 7 ml
EUR 499
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V2153SAF-100UG 100 ug
EUR 499
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7875-100UG 100 ug
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7875-20UG 20 ug
EUR 219
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7875SAF-100UG 100 ug
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7878-100UG 100 ug
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7878-20UG 20 ug
EUR 219
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7878SAF-100UG 100 ug
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7879-100UG 100 ug
EUR 499
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

Lambda Light Chain Antibody / Lambda Antibody

V7879-20UG 20 ug
EUR 219
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant.

C-reaktives  Protein-  Albumin-Verhältnis (CAR) als Prädiktor für Anastomoseninsuffizienz in der kolorektalen Chirurgie

Hintergrund:  Anastomoseninsuffizienz (AL) ist eine der schwerwiegendsten Komplikationen in der kolorektalen Chirurgie. Derzeit sind keine prädiktiven Biomarker für AL verfügbar. Das Ziel dieser Studie warfare es, die Rolle des C-reaktiven Proteins (CRP) zu Albumin- Verhältnis (CAR) als Prädiktor für AL bei Patienten zu untersuchen, die sich einer elektiven Operation wegen Darmkrebs unterziehen.

Materials und Methoden: Es wurden  Daten von 1183 konsekutiven Patienten erhoben, die in den an der Studie beteiligten chirurgischen Einheiten wegen histologisch nachgewiesenem Dickdarmkrebs operativ behandelt wurden. Die Daten umfassten Geschlecht, Alter, BMI, ASA-Rating, Charlson-Komorbiditätsindex, Lokalisation, Histologie und Stadium der Erkrankung sowie Bluttests einschließlich Albumin und CRP am 4. postoperativen Tag. Unterschiede in CAR zwischen Patienten, die AL entwickelten und denen, die keine AL entwickelten, wurden analysiert, und die Fähigkeit von CAR, AL vorherzusagen, wurde mit ROC-Analyse untersucht.

Ergebnisse:  CAR warfare bei Patienten mit AL signifikant höher als bei Patienten ohne, am 4. postoperativen Tag. In der ROC-Analyse zeigte CAR eine gute Fähigkeit zum Nachweis von AL (AUC 0,825, 95% CI: 0,786-0,859), größer als die von CRP und Albumin allein. CAR zeigte auch eine hohe Fähigkeit, postoperative Todesfälle zu erkennen (AUC 0,750, 95% CI 0,956–0,987). Diese Ergebnisse wurden in einer multivariaten Analyse unter Einbeziehung der relevantesten Risikofaktoren für AL bestätigt.

Schlussfolgerung:  Unsere Studie zeigte, dass CAR, ein kostengünstiger und weit verbreiteter Laborbiomarker, AL und Tod bei Patienten, die sich einer elektiven Operation wegen Darmkrebs unterzogen haben, angemessen vorhersagt.

Die Rolle von TRIM-  Proteinen  in PRR-Signalwegen und immunvermittelten Erkrankungen

Mustererkennungsrezeptoren (PRRs) sind eine Artwork Erkennungsmolekül , das hauptsächlich auf Zellen des angeborenen Immunsystems exprimiert wird. PRRs erkennen eine oder mehrere Arten von Pathogen-assoziierten molekularen Mustern (PAMPs), die die Produktion von Interleukin (IL), Tumornekrosefaktor (TNF), Interferon (IFN) und anderen verwandten Zytokinen induzieren, um immunvermittelte Krankheiten zu verschlimmern. PPR-Signalwege spielen sowohl im angeborenen als auch im adaptiven Immunsystem eine wichtige Rolle und sind leicht zu aktivieren oder zu regulieren.

Tripartite Motiv (TRIM) Proteine ​​sind eine Gruppe von hochkonservierten Proteinen in der Struktur. Die meisten TRIM-Proteine ​​enthalten eine RING-Domäne, von der angenommen wird, dass sie eine Rolle bei der Ubiquitinierung spielt. TRIM-Proteine ​​sind an der viralen Immunität, Entzündungsreaktion, Autophagie und Tumorwachstum beteiligt. In diesem Evaluation konzentrieren wir uns auf die Regulation von TRIM-Proteinen auf PRR-Signalwegen und ihre Rolle bei immunvermittelten Erkrankungen.

Rekonstituierte kryokonservierte Blutplättchen synthetisieren  Proteine  während der Kurzzeitlagerung und verpacken eine definierte Untermenge in Mikrovesikel

Hintergrund: Die  Kryokonservierung von Thrombozyten (PLTs) könnte ihre Haltbarkeit auf Jahre verlängern, verglichen mit Tagen für flüssig gelagerte Thrombozyten. Aufgrund ihrer stärkeren hämostatischen Wirkung könnten rekonstituierte kryokonservierte Thrombozyten (Kryo-PLTs) Blutungsnotfälle unterstützen. Da die Proteinsynthese mit PLT-Funktionen wie Gerinnselbildung und Immunantworten in Verbindung gebracht wurde, wurde die Translationskapazität rekonstituierter Kryo-PLTs nach Auftauen und kurzzeitiger Lagerung untersucht.

Methoden/Materialien:  Blutplättchen wurden bei –80°C mit 5-6% DMSO eingefroren. Nach dem Auftauen wurden sie in Plasma rekonstituiert und dann aliquotiert (12 ml) in Minibeutel und über 24 h Lagerung bei RT bewertet . Eine Serie diente als Kontrolle; die zweite und dritte Serie wurden entweder mit 300 μM Puromycin (Pm) oder 227 nM Biotin-markiertem Pm gespikt. Die Proben wurden auf In-vitro-Qualität und PLT-Mikrovesikelzählung mittels Durchflusszytometrie getestet. Die Proteinsynthese in Kryo-PLTs wurde mit einer modifizierten Methode bewertet, die auf Puromycin-assoziierter Proteomik der naszierenden Kette basiert.

Ergebnisse:  In-vitro-Parameter von rekonstituierten und anschließend gelagerten Thrombozyten stimmten mit zuvor veröffentlichten Ergebnissen überein. Massenspektrometrische Analysen ergaben, dass 22 Proteine ​​in PLTs synthetisiert wurden und 13 davon in Thrombozyten-Mikrovesikeln (PMVs) beobachtet wurden.

Schlussfolgerung:  Kryo-PLTs können nach Rekonstitution und Lagerung Proteine ​​synthetisieren . Die Entdeckung einer Untergruppe dieser Proteine ​​im PMV legt eine möglicherweise selektive Rolle bei der Vesikelverkapselung nahe. Diese Beobachtung liefert neue Einblicke in die Fähigkeit zur Proteinsynthese in Kryo-PLTs und die potenzielle Regulierung der Proteinverpackung in PMV.

Related Post

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert